The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has
According to information published on clinicaltrials.gov, the randomized, subject- and investigator-blinded study will enroll 60 obese adult patients with type 2 diabetes to assess the safety, pharmacokinetics and
This global Phase 2a clinical trial is being conducted in approximately 150 ambulatory patients diagnosed with influenza A. Patients in the Phase 2a clinical trial will be randomized
The marketing authorization allows for the marketing of TAF in the 28 countries of the European Union, Norway and Iceland. University of Milan Fondazione IRCCS Ca’ Granda Ospedale
Orphan drug designations are granted to drugs and biologics intended to treat rare diseases. The designation provides incentives to advance development of rare disease drugs and for commercialization
This multi-center, randomized, double-blind study was designed to compare the efficacy, safety and tolerability of intravenous and oral Debio 1450 at two dose regimens with intravenous vancomycin /
These projects will be conducted by leading academic institutions, non-profit organizations and community groups from around the world, focusing on three key areas: translational research, efficacy studies in
This is the first application for regulatory approval of KEYTRUDA in combination with another treatment. The FDA granted Priority Review with a PDUFA, or target action, date of
Zebra will use its novel and patented function-based antibody discovery platform to generate antibodies that activate biological pathways associated with targets designated by AbbVie. Zebra and AbbVie will
Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.